BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Peter Linde as CMO. Linde was VP of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN). NeoPhore Ltd....
...VP of manufacturing. Robin Sawka, BioCentury Staff National Institute for Health and Care Excellence (NICE) Bristol Myers Squibb Co. NeoPhore Ltd. Medicxi...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

...T cell therapies and cancer vaccines that either target or deliver the newly formed antigens. NeoPhore Ltd....
...and backup programs are in discovery, and NeoPhore expects to select a candidate in 2020. NeoPhore...
...into 2020, during which time NeoPhore will consider pursuing a financing or partnering. COMPANY PROFILE NeoPhore Ltd....
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...and SVP Kai Pinkernell will transition to CMO and chief development officer. Cancer immuno-oncology company NeoPhore Ltd....
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

...Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a...
...will seek to discover and develop small molecule immuno-oncology therapies to treat undisclosed cancer indications. NeoPhore...
...Fund. NeoPhore Ltd., Cambridge, U.K. PhoreMost Ltd., Cambridge, U.K. Business: Cancer Allison Johnson Cancer Research Technology Pioneer Fund PhoreMost Ltd. NeoPhore Ltd....
Items per page:
1 - 4 of 4
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Peter Linde as CMO. Linde was VP of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN). NeoPhore Ltd....
...VP of manufacturing. Robin Sawka, BioCentury Staff National Institute for Health and Care Excellence (NICE) Bristol Myers Squibb Co. NeoPhore Ltd. Medicxi...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

...T cell therapies and cancer vaccines that either target or deliver the newly formed antigens. NeoPhore Ltd....
...and backup programs are in discovery, and NeoPhore expects to select a candidate in 2020. NeoPhore...
...into 2020, during which time NeoPhore will consider pursuing a financing or partnering. COMPANY PROFILE NeoPhore Ltd....
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...and SVP Kai Pinkernell will transition to CMO and chief development officer. Cancer immuno-oncology company NeoPhore Ltd....
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

...Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a...
...will seek to discover and develop small molecule immuno-oncology therapies to treat undisclosed cancer indications. NeoPhore...
...Fund. NeoPhore Ltd., Cambridge, U.K. PhoreMost Ltd., Cambridge, U.K. Business: Cancer Allison Johnson Cancer Research Technology Pioneer Fund PhoreMost Ltd. NeoPhore Ltd....
Items per page:
1 - 4 of 4